309 related articles for article (PubMed ID: 33029680)
21. Management of pulmonary neuroendocrine tumors.
Ramirez RA; Chauhan A; Gimenez J; Thomas KEH; Kokodis I; Voros BA
Rev Endocr Metab Disord; 2017 Dec; 18(4):433-442. PubMed ID: 28868578
[TBL] [Abstract][Full Text] [Related]
22. Digestive neuroendocrine neoplasms: A 2016 overview.
Merola E; Rinzivillo M; Cicchese N; Capurso G; Panzuto F; Delle Fave G
Dig Liver Dis; 2016 Aug; 48(8):829-35. PubMed ID: 27212431
[TBL] [Abstract][Full Text] [Related]
23. Systemic therapies in patients with advanced well-differentiated pancreatic neuroendocrine tumors (PanNETs): When cytoreduction is the aim. A critical review with meta-analysis.
Pozzari M; Maisonneuve P; Spada F; Berruti A; Amoroso V; Cella CA; Laffi A; Pellicori S; Bertani E; Fazio N
Cancer Treat Rev; 2018 Dec; 71():39-46. PubMed ID: 30352319
[TBL] [Abstract][Full Text] [Related]
24. Medical Management of Pancreatic Neuroendocrine Tumors: Current and Future Therapy.
Chan JA; Kulke MH
Surg Oncol Clin N Am; 2016 Apr; 25(2):423-37. PubMed ID: 27013373
[TBL] [Abstract][Full Text] [Related]
25. Digestive neuroendocrine tumors (DNET): the era of targeted therapies.
Boussaha T; Rougier P; Taieb J; Lepere C
Clin Res Hepatol Gastroenterol; 2013 Apr; 37(2):134-41. PubMed ID: 23562338
[TBL] [Abstract][Full Text] [Related]
26. Hematological toxicity of combined 177Lu-octreotate radiopeptide chemotherapy of gastroenteropancreatic neuroendocrine tumors in long-term follow-up.
Kesavan M; Claringbold PG; Turner JH
Neuroendocrinology; 2014; 99(2):108-17. PubMed ID: 24714208
[TBL] [Abstract][Full Text] [Related]
27. Sunitinib in Tandem With 177 Lu-DOTATATE Therapy in Advanced Pancreatic Neuroendocrine Tumor : A New Treatment Approach.
Aggarwal P; Gunasekaran V; Sood A; Gupta K; Das CK; Mittal BR
Clin Nucl Med; 2024 Feb; 49(2):e85-e86. PubMed ID: 38109041
[TBL] [Abstract][Full Text] [Related]
28. Medical treatment of neuroendocrine tumours.
Weber HC
Curr Opin Endocrinol Diabetes Obes; 2013 Feb; 20(1):27-31. PubMed ID: 23221494
[TBL] [Abstract][Full Text] [Related]
29. Treatment of liver metastases in patients with digestive neuroendocrine tumors.
Rossi RE; Massironi S; Spampatti MP; Conte D; Ciafardini C; Cavalcoli F; Peracchi M
J Gastrointest Surg; 2012 Oct; 16(10):1981-92. PubMed ID: 22829240
[TBL] [Abstract][Full Text] [Related]
30. Systemic Therapies for Advanced Pancreatic Neuroendocrine Tumors.
Raj N; Reidy-Lagunes D
Hematol Oncol Clin North Am; 2016 Feb; 30(1):119-33. PubMed ID: 26614372
[TBL] [Abstract][Full Text] [Related]
31. Advances in Systemic Therapy for Gastroenteropancreatic Neuroendocrine Malignancies.
Halfdanarson TR; Strosberg JR
Curr Clin Pharmacol; 2015; 10(4):305-10. PubMed ID: 26548907
[TBL] [Abstract][Full Text] [Related]
32. Everolimus in combination with octreotide long-acting repeatable in a first-line setting for patients with neuroendocrine tumors: an ITMO group study.
Bajetta E; Catena L; Fazio N; Pusceddu S; Biondani P; Blanco G; Ricci S; Aieta M; Pucci F; Valente M; Bianco N; Mauri CM; Spada F
Cancer; 2014 Aug; 120(16):2457-63. PubMed ID: 24752410
[TBL] [Abstract][Full Text] [Related]
33. Systemic treatment of gastroenteropancreatic neuroendocrine tumors (GEP-NETS): current approaches and future options.
Strosberg JR
Endocr Pract; 2014 Feb; 20(2):167-75. PubMed ID: 24014009
[TBL] [Abstract][Full Text] [Related]
34. Therapeutic options in lung neuroendocrine tumors: between established concepts and new hopes.
Brighi N; Lamberti G; Manuzzi L; Maggio I; Campana D
Anticancer Drugs; 2019 Aug; 30(7):e0784. PubMed ID: 30896503
[TBL] [Abstract][Full Text] [Related]
35. Hitting the target: where do molecularly targeted therapies fit in the treatment scheduling of neuroendocrine tumours?
Karpathakis A; Caplin M; Thirlwell C
Endocr Relat Cancer; 2012 Jun; 19(3):R73-92. PubMed ID: 22474226
[TBL] [Abstract][Full Text] [Related]
36. Advances in the management of unresectable or metastatic pancreatic neuroendocrine tumors: chemotherapy, targeted therapy, hormonal treatment, and future directions.
Bilici A
Asian Pac J Cancer Prev; 2015; 16(6):2151-9. PubMed ID: 25824731
[TBL] [Abstract][Full Text] [Related]
37. Predictive Markers of Response to Everolimus and Sunitinib in Neuroendocrine Tumors.
Martins D; Spada F; Lambrescu I; Rubino M; Cella C; Gibelli B; Grana C; Ribero D; Bertani E; Ravizza D; Bonomo G; Funicelli L; Pisa E; Zerini D; Fazio N;
Target Oncol; 2017 Oct; 12(5):611-622. PubMed ID: 28634872
[TBL] [Abstract][Full Text] [Related]
38. Treatment sequence in patients with neuroendocrine tumours: a nationwide multicentre, observational analysis of the Swiss neuroendocrine tumour registry.
Kollar A; Bütikofer L; Ochsenbein A; Stettler C; Trepp R
Swiss Med Wkly; 2020 Jan; 150():w20176. PubMed ID: 31940430
[TBL] [Abstract][Full Text] [Related]
39. Real-world study of everolimus in advanced progressive neuroendocrine tumors.
Panzuto F; Rinzivillo M; Fazio N; de Braud F; Luppi G; Zatelli MC; Lugli F; Tomassetti P; Riccardi F; Nuzzo C; Brizzi MP; Faggiano A; Zaniboni A; Nobili E; Pastorelli D; Cascinu S; Merlano M; Chiara S; Antonuzzo L; Funaioli C; Spada F; Pusceddu S; Fontana A; Ambrosio MR; Cassano A; Campana D; Cartenì G; Appetecchia M; Berruti A; Colao A; Falconi M; Delle Fave G
Oncologist; 2014 Sep; 19(9):966-74. PubMed ID: 25117065
[TBL] [Abstract][Full Text] [Related]
40. Medical management of gastrointestinal neuroendocrine tumors.
Perez K; Chan J
Curr Opin Endocrinol Diabetes Obes; 2022 Apr; 29(2):219-224. PubMed ID: 35045527
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
